Robert Wertheimer, MD
Ophthalmology · West Caldwell, NJNPI 1972692598
Payments from drug & device makers
Across 135 payments — averaging $26.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$410
- Glaukos Corporation$351
- AbbVie$336
- Tarsus Pharmaceuticals, Inc.$328
- NEW World Medical,inc.$324
- Bausch & Lomb Americas Inc.$260
- plus $2K from 18 others
What the payments were for
- Food & beverage$3,532100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 24 | $410 |
| Glaukos Corporation | 3 | $351 |
| AbbVie(2 entities) | 23 | $336 |
| Tarsus Pharmaceuticals, Inc. | 8 | $328 |
| NEW World Medical,inc. | 3 | $324 |
| Bausch & Lomb Americas Inc. | 10 | $260 |
| Sun Pharmaceutical Industries Inc. | 9 | $240 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $234 |
| Biotissue Holdings Inc. | 3 | $204 |
| Ocular Therapeutix, Inc. | 8 | $125 |
| Dompe US, Inc. | 2 | $122 |
| Oyster Point Pharma, Inc. | 6 | $104 |
| Kala Pharmaceuticals, Inc. | 6 | $100 |
| Novartis | 5 | $69 |
| Eyevance Pharmaceuticals LLC | 3 | $48 |
| Johnson & Johnson Vision Care, Inc. | 2 | $44 |
| Shire North American Group Inc | 3 | $43 |
| Amgen | 2 | $33 |
| Harrow Eye, LLC | 2 | $32 |
| Sight Sciences, Inc. | 2 | $32 |
| Aerie Pharmaceuticals, Inc. | 2 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $28 |
| Coopervision Inc. | 1 | $19 |
| Visioneering Technologies, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$227
- XDEMVY$216
- Tecnis IOL$146
- Ahmed Glaucoma Valve$120
- Kahook Dual Blade$120
- iStent inject Trabecular Micro-Bypass Stent System$112
- iDoseTR$111
- Oxervate$108
- AmnioGraft$107
- CEQUA$107
How this compares
$3,532 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 19 | $27,522 |
| LumiganBimatoprost | 32 | $17,634 |
| TyrvayaVarenicline Tartrate | 11 | $11,649 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $8,011 |
| Timolol Maleate | 180 | $7,713 |
| Prednisolone Acetate | 175 | $6,558 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $5,903 |
| Latanoprost | 445 | $5,444 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $4,330 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,886 |
| ProlensaBromfenac Sodium | 11 | $3,752 |
| Travoprost | 22 | $3,569 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 114 | $2,566 |
| Ketorolac Tromethamine | 73 | $2,233 |
| Brinzolamide | 11 | $1,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $336 | $53,16766 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $104 | $11,64911 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $29 | $5,90314 claims |
| AlconSimbrinza | $410 | $3,88615 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $28 | $3,75211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in West Caldwell
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.